Sun Pharma Acquires Organon in $11.75B Deal
By ThePip Desk•
Scientists review data in a brightly lit pharmaceutical lab.
Key Highlights
Sun Pharma to acquire Organon & Co in a $11.75B all-cash deal. Acquisition expands Sun Pharma’s portfolio in women’s health and biosimilars.
Sun Pharmaceutical Industries has reached an agreement to acquire U.S. drugmaker Organon & Co in an all-cash transaction valued at approximately $11.75 billion, which includes debt.
Under the terms of the agreement, Sun Pharma will purchase all outstanding shares of Organon for $14.00 per share. This acquisition will result in Sun Pharma assuming full ownership of Organon, a company with a focus on women’s health, biosimilars, and established medicines.